Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15143)	2/15/1998 5:19:00 PM
From: squetch	Read Replies (4) \| Respond to of 32384

In the info on Tamoxifen I read, it appeared to work best for Estrogen Receptor positive patients w/ soft tissue(ie non bone metastized) tumors. Henry, would you explain Estrogen positive and negative receptors? squetch The following might give an idea of Tamox. trial results. It would be interesting to me to compare the original Tamox rat data w/ current rat info and Tamox trial data. ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov